Furosemide Use in Chronic Kidney Disease Patients
Abstract
Chronic kidney disease is defined as kidney disease occurring for more than three months and is characterized by a decreasing glomerular filtration rate, reaching below 60 mL/min/1.73 m2 . Decreased kidney function can reduce the kidney’s capacity to excrete sodium. Excess extracellular fluid will cause hypertension, and lower and upper extremity edema. Loop diuretics, such as furosemide, are known to increase sodium excretion by 20%, thereby reducing the amount of extracellular fluid. This study aimed to determine the patterns of furosemide use in chronic kidney disease patients at University of Muhammadiyah Malang General Hospital. Observational, descriptive, and retrospective data collection methods were used. The use of a single furosemide pattern was given to 25 patients (40%); a two-combination to 12 patients (20%); a three-combination to 9 patients (15%); a four-combination to 12 patients (20%); and a five-combination to 4 patients (5%). The most commonly used single furosemide was furosemide (3 x 40 mg, intravenous [iv]), which was administered to 16 patients (73%); the most common two-combination was furosemide (3 x 40 mg, iv) + amlodipine (1 x 10 mg, oral), which was given to 2 patients (20%); the most common three-combination was furosemide (3 x 40 mg, iv) + candesartan (1 x 16 mg, oral) + amlodipine (1 x 5 mg) and furosemide (3 x 40 mg, iv) + candesartan (1 x 16 mg, oral) + amlodipine (1 x 10 mg, oral), which was given to 2 patients (23%); the most common four-combination was furosemide (3 x 40 mg, iv) + nifedipine (3 x 10 mg, oral) + clonidine (3 x 0.15 mg, oral) + captopril (2 x 25 mg, oral), which was given to 3 patients (28%); and the most common five-combination was given to 1 patient (25%) with 4 patterns. In short, there were 22 patterns of furosemide switch therapy.
Keywords: furosemide, edema, chronic kidney disease
References
[1] Cecily V. DiPiro., Pharmacotherapy Handbook Ninth Edition., 2015.
[2] G.B. of Disease, “Global Facts: About Kidney Disease.,” p. 2010.
[3] S. Siregar and M.I. Karim, “CHARACTERISTICS OF CHRONIC KIDNEY DISEASE PATIENTS TREATED IN HOSPITAL.,” vol. 4, no. 4, pp. 82–85, 2019.
[4] Riskesdas, “Ginjal Kronik.,” p. 2013.
[5] L. D’Marco, M.J. Puchades, M. Romero-Parra, et al., “Coronavirus disease 2019 in chronic kidney disease.,” Clinical kidney journal. vol. 13, no. 3, pp. 297–306, 2020.
[6] B. Linelejan, O. Umboh, and F.E.N. Wantania, “Pengaruh penggunaan angiotensin converting enzyme inhibitor (ACEI) dan angiotensin receptor blocker (ARB) pada pasien coronavirus disease 2019 (covid-19) dengan hipertensi.,” e-CliniC. vol. 9, no. 1, p. 2021.
[7] M. Rachel L. Perlman, M. Michael Heung, MD, and M. Joachim H. Ix, Pathophysiology. of Disease: An Introduction to Clinical Medicine., 2015.
[8] R. Claure-Del Granado and R.L. Mehta, “Fluid overload in the ICU: evaluation and management.,” BMC nephrology. vol. 17, no. 1, pp. 1–9, 2016.
[9] W. Mulyaningsih, “Uji Efek Diuretik Ekstrak Etanol Daun Sukun Artocarpus Altilis (Parkinson) Fosberg terhadap Tikus Jantan Galur Wistar,” (2016).
[10] L. Ervani, D. Bahrun, and H.I. Lestari, “Tatalaksana Penyakit Ginjal Kronik pada Anak.,” Majalah Kedokteran Sriwijaya. vol. 47, no. 2, pp. 144–149, 2015.
[11] S. Tjekyan, “Prevalensi dan faktor risiko penyakit ginjal kronik di RSUP Dr. Mohammad Hoesin Palembang tahun 2012.,” Majalah Kedokteran Sriwijaya. vol. 46, no. 4, pp. 275–281, 2014.
[12] A. Arianti, A. Rachmawati, and E. Marfianti, “KARAKTERISTIK FAKTOR RISIKO PASIEN CHRONIC KIDNEY DISEASE (CKD) YANG MENJALANI HEMODIALISA DI RS X MADIUN.,” Biomedika. vol. 12, no. 1, pp. 36–43, 2020.
[13] R.F. Laily, “STUDI PENGGUNAAN FUROSEMID PADA PASIEN SINDROM NEFROTIK (Penelitian Dilakukan di RSUD Dr. Saiful Anwar Malang),” (2019).
[14] BPJS Kesehatan, “Penyakit Katastropik yang Menelan Biaya Besar BPJS Kesehatan 2019.,”
[15] G.N.M. Masi and R. Kundre, “Perbandingan Kualitas Hidup Pasien Gagal Ginjal Kronik Dengan Comorbid Faktor Diabetes Melitus Dan Hipertensi Di Ruangan Hemodialisa RSUP. Prof. Dr. RD Kandou Manado.,” Jurnal Keperawatan. vol. 5, no. 2, p. 2018.
[16] S.W. Oh and S.Y. Han, “Loop diuretics in clinical practice.,” Electrolytes & Blood Pressure: E & BP. vol. 13, no. 1, p. 17, 2015.
[17] I.B.N. Mahendra, “KRISIS HIPERTENSI.,” pp. 1–12, 2017.
[18] S.K. Frazier, J. Higgins, A. Bugajski, A.R. Jones, and M.R. Brown, “Adverse reactions to transfusion of blood products and best practices for prevention.,” Critical Care. Nursing Clinics. vol. 29, no. 3, pp. 271–290, 2017.